Back to Journals » OncoTargets and Therapy » Volume 6
Nimotuzumab as a radiosensitizing agent in the treatment of high grade glioma: challenges and opportunities
Authors Diaz-Miqueli A, Martinez GS
Received 29 March 2013
Accepted for publication 1 June 2013
Published 24 July 2013 Volume 2013:6 Pages 931—942
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Arlhee Diaz-Miqueli,1,* Giselle Saurez Martinez2,*
1Department of System Biology, Center of Molecular Immunology, Havana, Cuba; 2Medical Division, Center of Molecular Immunology, Havana, Cuba
*Both authors contributed equally to this manuscript
Abstract: Nimotuzumab is a humanized monoclonal antibody that binds specifically to human epidermal growth factor receptor, blocking receptor activation. Evidence of its radiosensitizing capacity has been widely evaluated. This article integrates published research findings regarding the role of nimotuzumab in the treatment of high grade glioma in combination with radiotherapy or radiochemotherapy in adult and pediatric populations. First, the mechanisms of action of nimotuzumab and its current applications in clinical trials containing both radiation and chemoradiation therapies are reviewed. Second, a comprehensive explanation of potential mechanisms driving radiosensitization by nimotuzumab in experimental settings is given. Finally, future directions of epidermal growth factor receptor targeting with nimotuzumab in combination with radiation containing regimens, based on its favorable toxicity profile, are proposed. It is hoped that this review may provide further insight into the rational design of new approaches employing nimotuzumab as a useful alternative for the therapeutic management of high grade glioma.
Keywords: nimotuzumab, radiation, high grade gliomas
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.